Evaluation of dermatological safety and adverse reaction of Tactivin Immunoplus (Immunomodulator) cream, Tactivin Anti Wrinkle cream and Tomicid (Antibacterial peptide) cream along with their Placebo with a 48 hours closed patch skin sensitization test on 24 healthy adult volunteers
Not Applicable
Completed
- Registration Number
- CTRI/2011/11/002112
- Lead Sponsor
- Remedia Therapeutics Pvt Ltd
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 24
Inclusion Criteria
Healthy male and female adult volunteers
Subjects willing to give a written informed consent.
Subjects age group 18 - 55 years
Subjects willing to maintain the patch test in position for 48 hours
Subject has not participated in a similar investigation in the past two weeks.
Subjects willing to come for regular follow up.
Subjects ready to follow instructions during the study period.
Exclusion Criteria
The investigator can decide to withdraw a subject from the trial at any moment because
One of the criteria of non inclusion occurred during the period of observation.
Indication of intolerance to the studied product requiring that the investigation should
be stopped.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method dermatological safety and adverse reaction of tactivin immunoplus cream, tactivin anti wrinkle cream and tomicid creamTimepoint: 0hrs 48hrs 96hrs 168hrs
- Secondary Outcome Measures
Name Time Method ot applicableTimepoint: Not applicable